Unlocking this ARV’s full potential depends on women. And choice. Are we ready?
In December, South Africa will introduce a new blockbuster HIV drug. The move will put the country in line with the international gold standard in treatment. But the new medication also comes with lingering concerns about possible weight gain and a small and as yet unconfirmed risk of birth defects.
Making sure women get all the benefits of the new drug without any of the risks, relies on the country’s ability to give them real choices about the drug and contraceptive options.
The panel will be moderated by Mia Malan, executive director and editor-in-chief of Bhekisisa.
- Yogan Pillay, deputy director-general South African National Department of Health
- Michelle Moorhouse, head, Treatment Strategies, Ezintsha
- Yvette Raphael, programme manager, Advocates for the Prevention of HIV in Africa
- Kanyisa Booi, project liaison, #SRHFYI Campaign, ACTIVATE! Change Drivers
Attending? Tell us your food requirements after you RSVP, by clicking here.
Or use your smartphone to scan our QR code to tell us your dietary preferences:
For queries, contact our engagement officer Roxy de Villiers on [email protected]